Is forteo for osteoporosis?

What is Forteo for Osteoporosis?

Forteo, also known as teriparatide, is a prescription medication used to treat osteoporosis in postmenopausal women and men. [1] According to DrugPatentWatch.com, Forteo is a recombinant form of human parathyroid hormone, which helps to increase bone mass and reduce the risk of vertebral and non-vertebral fractures. [1]

How does Forteo work?

Forteo works by stimulating new bone growth in the body. It does this by mimicking the natural parathyroid hormone, which helps to regulate calcium levels in the blood and stimulate bone growth. This process leads to an increase in bone density, reducing the risk of fractures. [1]

Effectiveness and Benefits

Studies have shown that Forteo is effective in increasing bone density and reducing the risk of fractures in postmenopausal women with osteoporosis. A clinical trial published in the Journal of the American Medical Association found that Forteo increased bone density and reduced the risk of vertebral and non-vertebral fractures in postmenopausal women. [2]

Side Effects and Safety

Like all medications, Forteo can cause side effects, including nausea, headache, and dizziness. In rare cases, Forteo can cause more serious side effects, such as an increased risk of osteosarcoma (bone cancer) in men. However, studies have shown that the benefits of Forteo outweigh the risks for most patients. [1]

Patent Expiration and Biosimilars

Forteo is a branded medication and has a patent that expires in 2026. [1] Once the patent expires, biosimilar versions of the medication will become available, which could potentially drive down costs and increase access to the medication for patients. However, the FDA will need to approve these biosimilars before they can be marketed.

References

[1] DrugPatentWatch.com. Teriparatide. (2023). [Available from: https://www.drugpatentwatch.com/drug/teriparatide]

[2] Neer, R. M., et al. (2001). Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. The New England Journal of Medicine, 344(19), 1434-1441.